Barclays
KYNB

Barclays’s Kyntra Bio KYNB Stock Holding History

Barclays’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-196
Closed -$130K – 4822
2021
Q2 		$130K Buy
+196
New +$113K ﹤0.01% 3742
2019
Q3 		– Sell
-48
Closed -$54K – 6823
2019
Q2 		$54K Sell
48
-276
-85% -$302K ﹤0.01% 6054
2019
Q1 		$440K Buy
324
+284
+710% +$385K ﹤0.01% 4235
2018
Q4 		$46K Buy
40
+24
+150% +$27K ﹤0.01% 5516
2018
Q3 		$24K Buy
+16
New +$24.6K ﹤0.01% 6408
2018
Q2 		– Sell
-1,080
Closed -$1.25M – 7051
2018
Q1 		$1.25M Buy
+1,080
New +$1.42M ﹤0.01% 2956

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Barclays's KYNB Position: Q2 2025 in Review

Barclays held its Kyntra Bio (KYNB) position steady in Q2 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5360.

Barclays first reported a position in KYNB in Q4 2014 and has held it in 38 quarters since. The position peaked at $8.1M in Q4 2019. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.

  • Barclays held 0 shares of Kyntra Bio worth $0 as of Q2 2025.
  • Barclays left its Kyntra Bio share count unchanged in Q2 2025.
  • Kyntra Bio made up ﹤0.01% of Barclays's portfolio in Q2 2025, its #5360 holding.
  • Barclays first reported a position in Kyntra Bio in Q4 2014 and has held it in 38 quarters since.
  • Barclays's Kyntra Bio position peaked at $8.1M in Q4 2019.
  • 30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.